Recurrence score (RS) differences between primary and second-primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry.
Shlomit Strulov Shachar(Tel Aviv Sourasky Medical Center), Salomon M. Stemmer(Tel Aviv University), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), Margarita Tokar, Tamar Yablonski‐Peretz(Hadassah Medical Center), Shulamith Rizel(Rabin Medical Center), Bella Kaufman(NYU Langone Health), Avital Bareket‐Samish, Ariel Hammerman(Clalit Health Services), Rinat Yerushalmi(Rabin Medical Center), Michelle Leviov(Haifa Medical Center), Amir Sonnenblick(Tel Aviv University), Addie Dvir(Teva Pharmaceuticals (Israel)), Georgeta Fried(Roche (Switzerland))
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k